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Abstract
Estrogens play an important role in the development and progression of several types of 
cancers. The synthesis of estrogens occurs in almost all tissues of the body in addition to 
the gonads. The enzyme aromatase (CYP19A1) encoded by CYP19A1 gene is involved in 
the synthesis of estrogens. Genetic variations in CYP19A1 gene influence both the struc-
ture-function relationship of the enzyme and the rate of its synthesis. Extensive studies 
have reported different types of polymorphisms in the CYP19A1 gene and have shown 
that the polymorphisms, depending on their location in the gene, have different effects on 
the function and activity of the gene product. Association studies have been conducted 
and have led to the realization that interpopulation differences are widespread. Not only 
do polymorphic forms exert different effects on the development of different cancers, 
due possibly to the influence of other genetic variations, environmental, metabolic, and 
epigenetic factors, but also are important as they lead to the interindividual differences 
seen during treatment of the cancer state. This chapter covers important aspects of the 
aromatase function, the CYP19A1 gene structure, polymorphisms identified in the gene, 
different cancers and associated polymorphisms, and the role of the polymorphic forms 
in affecting the treatment strategies.
Keywords: aromatase, aromatase inhibitors, cancer, CYP19A1, estrogens, 
polymorphism
1. Introduction
By the late 1990s, several epidemiological and clinical studies had shown that estrogens play 
an important role in the development and progression of several types of cancers, in particular 
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breast, endometrial, prostrate, and colorectal cancer (CRC). A strong connection was shown 
to exist between initiation/promotion of cancer and excess of estrogens, as the latter increased 
mitotic activity. Initially, extensive studies linked the administration of exogenous hormones 
to the development of these cancers [1], and later it was shown that several estrogen-sensitive 
tissues act as intracrine organs, producing estrogens and hence elevating local hormone lev-
els, which accelerated proliferation and growth of cancer cell [2].
There are four major naturally occurring estrogens, estrone (E1), estradiol (E2), estriol (E3), 
and estetrol (E4), which are produced only during pregnancy. Estradiol (E2) is an important 
estrogen, has the highest affinity to estrogen receptors, and is required for different physi-
ological functions during all stages of life in both males and females [3]. Aromatase, due to its 
critical role in the synthesis of the different forms of estrogens from androgens [4], specifically 
estradiol from testosterone, estrone from androstenedione, and estriol from 16α-hydroxylated 
dehydroepiandrosterone, is incriminated as a major player in cancer biogenesis.
2. The enzyme “aromatase”: a key player in estrogen synthesis
Aromatase (EC 1.14.14.1), also known as estrogen synthase, is the gene product of CYP19A1 
gene and is an important member of the cytochrome p450 superfamily, subfamily 19. It cata-
lyzes a rate-limiting step during the aromatization of androgens to estrogens by three succes-
sive hydroxylations and eliminations of carbon at position 19 of the androgens (Figure 1) [5].
Figure 1. Role of aromatase in estrogen synthesis.
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Several studies suggest that many tumors are dependent upon estrogens for their develop-
ment and continued growth [6]. Blockage of any conversion in the pathway potentially leads 
to decreased estrogen production, but more specific suppression results from inhibition of the 
final step that is unique to estrogen biosynthesis, i.e., inhibition of aromatase. The key role of 
aromatase in estrogen biosynthesis has generated enormous interest in putative inhibitors of 
the enzyme and their use as therapy against endocrine-responsive tumors.
Initially, it was believed that the ovaries and placenta are the only site for the production of 
estrogens, which are involved in female reproductive functions. However, later studies con-
ducted using many sophisticated and sensitive tests and equipment revealed that estrogens 
are also synthesized in the male gonadal tissues, i.e., the testis and epididymis, and in extra-
gonadal tissues including liver, colon, prostate, brain, adrenal gland, skin, bone, hair follicles, 
adipose, and vascular tissues. This is due to the presence of aromatase, which is active in 
various tissues in both females and males, and hence estrogens are produced in gonads and 
in the extra-gonadal tissues [2, 7–9].
Aromatase is a dimer, a complex of two polypeptides; one is a specific cytochrome P450, 
which is the product of the CYP19A1 gene. The other subunit is a flavoprotein, NADPH-
cytochrome P450 reductase. This is ubiquitously present in most cells, and this wide distribu-
tion within the human body justifies its central role in different physiological processes [10].
2.1. Aromatase gene structure
The CYP19A1 is located on chromosome 15 at q21.1 region and spans about 123 kb [11]. It has 
10 exons and nine introns in all tissues where the coding region covers about 34 kb region, 
while the regulatory region is more than three times longer (approx. 95 kb) (Figure 2). This is 
in the 5′ region of the gene and occurs as unique sequences, scattered upstream of the coding 
sequences. The regulatory region is unusually large and is composed of at least 10 tissue-
specific promoters (Figure 3). These promoters are used alternatively in different cell types. 
The regulation of each promoter depends on a distinct set of regulatory sequences in the DNA 
and specific transcription factors that bind to these sequences. The transcription factors bind 
the promoter, activating it and giving rise to splicing of an untranslated first exon onto this 
common junction immediately upstream of the translation start site in the coding region. The 
promoter region has the basic transcription elements, i.e., the TATA box, a CAAT box, and a 
GC box, and also contains different regulatory elements in different tissues [12].
This first exon (exon 1) occurs in multiple forms, which encode the 5′ untranslated region (UTR) 
of the CYP19A gene and are spliced out in a highly tissue-specific manner. Since the gene has 
multiple promoters, in each tissue the transcript is generated following tissue-specific splicing of 
alternative exons available for exon 1. For physiologic estrogen biosynthesis in the gonads, brain, 
vascular tissue, bone, adipose tissue, placenta, skin, and fetal liver, different partially tissue-
specific promoters are used [13]. To date, nine different exon 1 subtypes have been reported, 
and each is expressed in a specific tissue as presented in Table 1. Exons 2–10 form the coding 
sequence of the gene and lie in a region, which is approximately 34 Kb in length. Exon 1, specific 
for the tissue, gets linked to exon 2 after splicing of the intervening sequences (Figure 3). All 
transcripts have the same coding sequence generated from the sequences in exons 2–10 [12–14].
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Investigations have shown the expression of aromatase gene in estrogen-dependent breast can-
cer (BC) tissues, endometrial carcinoma, and colorectal, gastric, liver, lung, ovarian, pancreatic, 
and prostatic cancers [2, 12]. The cell-specific expression of aromatase determines the presence 
or absence of aromatase activity in the tissue and hence the amount of available estrogens. 
Exon 1 type Expressed in (tissue)
I.1 (1a) and I.2 (1e) —Placenta
I.3 (1c) and PII (1d) —Ovary
—Testis
I.4 (1b) —Adipose tissue
I.5 —Fetal lung
—Intestine
I.6 —Adipose
—Bone tissues
I.7 —Adipose
—Vascular endothelial tissues
1f —Brain
II. I.3, I.7, and I.4 —Breast
Table 1. The multiple forms of exon 1 and the tissues in which each is expressed.
Figure 2. Structure of CYP19A gene.
Figure 3. The 5′ gene region of the human CYP19A1 gene. The 5′ untranslated region of the human aromatase gene is 
encoded by multiple exon 1. These are tissue specifically spliced and connected to exon 2 (modified from Ref. [4]). The 
lines linking exon 1 to exon 2 indicate that exon 1 is present as 5′ UTR in the tissue.
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The transcriptional regulation of aromatase has been extensively investigated since the 1980s. 
Many mechanisms have been proposed to explain the underlying control of CYP19A1 gene 
expression, in an attempt to elucidate the etiological role played by aromatase in cancer devel-
opment and progression [15]. Several mechanisms at the transcriptional, posttranscriptional, 
and epigenetic levels have been unveiled. In addition to these mechanisms, extensive genetic 
variants of CYP19A1 gene have been identified that influence aromatase activity and may be 
regarded as prognostic factors for susceptibility to cancer development [16–18].
2.2. Genetic polymorphisms of the CYP19A1 gene
The CYP19A gene seems to have acquired a number of variations in the coding, noncoding, and 
control sequences [17]. These variations result from different mutations, short tandem repeat 
(STR) polymorphisms, and single nucleotide polymorphisms (SNPs). The variations may influ-
ence expression of CYP19A1 gene, activity of the enzyme, susceptibility to cancer development, 
and clinicopathological features of cancer, and some act as refractory and prognostic factors.
Frequencies at which the alleles occur in different populations differ considerably, and it is 
also shown that the differences in the plasma levels of several sex hormones may be due to 
the presence of different alleles, particularly in postmenopausal women. It is hypothesized 
that the genetic polymorphisms provide a probable explanation for differences in cancer risk 
among different ethnic groups. Hence, the presence of the different CYP19A1 alleles may 
account partially for the racial differences in the frequency of the different types of cancer.
This section presents the polymorphisms identified in the CYP19A1 gene and discusses their 
distribution in different populations, their association with different cancers, their influence 
on the development, prognosis, treatment strategies, and complications resulting from the 
treatment.
2.2.1. Short tandem repeat (STR) polymorphism
Short tandem repeats (STRs) were identified in the aromatase gene during the late 1990s, and 
some studies showed a higher incidence of cancers in individuals carrying different alleles of 
the CYP19A1 gene. One of the most frequently reported STRs in CYP19A1 is a tetranucleotide 
(TTTA) sequence, which occurs in different repeats ranging from 2 to 13.
Several studies conducted in different populations reported association between the tetra-
nucleotide repeat sequence and cancer, while others failed to do so. Kristensen et al. [19] 
reported that a rare polymorphic A1 allele of CYP19 repeat (TTTA)12 occurs at a significantly 
higher frequency in females suffering from breast cancer than controls (3.6 vs. 1.6%) and 
indicated that the carriers of the allele might have an increased risk of developing breast 
cancer (OR = 2.42; 95% CI = 1.03–5.80). Haiman et al. [20] showed that breast cancer cases 
had a statistically significant greater frequency of the (TTTA)10 repeat alleles (10 alleles; 
2.3 vs. 0.7%; p = 0.005), but a nonsignificant increase in the frequency of the (TTTA)12 allele 
(12 alleles; 3.1 vs. 2.1%; p = 0.11). The 10 alleles were more frequent in patients with more 
advanced cancer disease, which were defined as four or more involved nodes or distant 
metastasis. A little later study on Japanese women reported similar results in breast cancer 
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(OR = 1.80; 95% CI = 0.97–3.36) risk [21]. Baxter et al. [22] also confirmed that breast can-
cer cases had a statistically significant positive association with the (TTTA)10 allele (1.5 vs. 
0.2%; p = 0.028) and the (TTTA)8 allele (13.5 vs. 8.7%; p = 0.012), while the frequency of the 
(TTTA)12 allele was not statistically significant. A study by Miyoshi et al. [23] showed that 
the (TTTA)7 along with a trinucleotide deletion (−3bp) allele was increased significantly (p < 
0.05) in breast cancer patients who were ER positive (OR = 1.72; 95% CI = 1.10–2.69), but not 
those who were ER negative. Among the Brazilian cancer patients, the (TTTA)10 allele asso-
ciated positively with breast cancer development and the frequency of the allele was three 
times more compared to controls (p = 0.048) [24]. A study from China also showed a signifi-
cantly higher frequency of (TTTA)10 allele in breast cancer cases (12.4%) than controls (8.2%) 
(p = 0.02) [25]. As presented in Figure 4, a recent study from Mexico showed significant 
differences in the repeat number in breast cancer patients compared to the normal controls.
Several studies were published from Russia, and it was shown by Artamonov et al. [26] that the 
allele (TTTA)8 was associated with BC (11.8 vs. 6.3%; p = 0.04). Risk of BC elevated if this allele was 
present with genotype A2/A2 of the tetranucleotide deletion (7.3 vs. 0%; p < 0.01). In Norwegian 
women [19], the association of breast cancer with the long allele (TTTA)12 was shown.
Kim et al. [28] reported that though there is no difference in the (TTTA)n genotype distribu-
tion between patients and controls, but there was a positive association between >(TTTA)10 
and ER-negative tumors and between lower repeat polymorphism and ER-positive tumors 
(p = 0.019). A study on different ethnic groups (African-Americans, Japanese, Latinas, and 
non-Latina Whites) by Probst-Hensch et al. [29] reported contradictory results and showed no 
consistent association of (TTTA)n repeat polymorphism with breast cancer risk. This was in 
line with other studies from the USA [30] and Greece [31]. These studies show that the tetra-
nucleotide polymorphism occurs in different populations, and the repeat variants show asso-
ciation with breast cancer in some and not others. Often, contradictory results are reported 
from the same population.
Figure 4. Frequency of TTTA repeat number polymorphism in breast cancer (BC) patients and normal (N) controls in a 
Mexican population (modified from Ref. [27]).
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The (TTTA)n polymorphism has been reported to modify susceptibility to prostate cancer 
development in several studies in different populations. Most of the studies have shown that 
the longer alleles (TTTA)7 or more are associated with a higher risk of prostate cancer, and 
in some studies, it is shown that the association is also with cancer-specific survival [32, 33]. 
A study on the Japanese men reported that (TTTA)7 and (TTTA)8 alleles show association 
with the risk of prostate cancer [34]. It was also shown that when the patients were stratified 
according to the pathological grade or the clinical stage, there was no significant difference in 
the different genotypes. Tsuchiya et al. [35] regarded this polymorphism as a novel predictor 
of prostate cancer with bone metastasis. They showed that alleles longer than seven repeats 
(TTTA)7) were associated with worse cancer-specific survival. Tang et al. [36] further sug-
gested that though these repeat polymorphism influence disease susceptibility, but the effect 
is modified by factors that alter hormone metabolism.
The (TTTA)n has also been investigated in endometrial cancer, and some studies have shown 
that the long alleles A6 and A7 occur at a higher frequency in the patients than the controls 
[37–39]. It was shown that the longer A6 and A7 alleles have higher intratumoral aromatase 
activity, thus predisposing to increased synthesis of estrogens and hence increasing the local 
estrogen concentration, which supports proliferation [40].
2.2.2. TCT insertion/deletion in intron 4
A TCT insertion/deletion (ins/del) polymorphism occurs in the intron 4 of the CYP19A gene, 
approximately 50 bp upstream to the (TTTA)n repeat. A few studies have linked breast can-
cer to the trinucleotide TCT deletion [31, 41]. In the British population, the TCT ins/del and 
a G-->T substitution in intron 4 were of rare occurrence (0.35 and 0.45, respectively), and 
both were in linkage disequilibrium with (TTTA)10 allele, which was reported to be linked to 
breast cancer susceptibility [41]. Similarly, in Korean breast cancer patients, 3-bp ins/del poly-
morphism showed a strong association with breast cancer risk [42], and other studies showed 
a stronger association with endometrial and prostate cancer risk [39, 43]. Coexisting (TTTA)n 
and 3-bp TCT deletion polymorphism show contradictory results in different studies [44, 45].
2.2.3. Single nucleotide polymorphisms
The presence of single nucleotide variations in the DNA sequence of CYP19A1 gene was rec-
ognized in the earlier 1990s, and Ma et al. [46] reported 88 SNPs in 2005. To date several more 
SNPs have been identified, and several are of clinical interest, due to their predisposing or 
protective role in the development of cancer or other diseases. Some of these variations are 
rare, while others occur at a frequency of >1% and are polymorphic. Sourdaine et al. in 1994 
[47] described several rare mutations in exons 3, 7, and 10 of the CYP19A gene in breast cancer 
patients. Kristensen et al. [48] reported a mutation in exon 10 (C > T) and showed that though 
the frequency of TT genotype was significantly higher in patients vs. controls (p = 0.007), par-
ticularly among those with stage III and IV diseases (p = 0.004) and with tumors larger than 
5 cm (p = 0.001), it was a rare mutation. The T allele frequency was considerably higher in indi-
viduals who presented with more advanced disease and had larger (>5 cm) tumor size. The 
aromatase mRNA levels were high in the patient group and were associated with a switch to 
ovarian promoter from the one normally used, i.e., adipose promoter.
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Single nucleotide polymorphism (SNP) association studies have been reported in several can-
cers and provide several interesting cues about the role of these variations. This section pres-
ents different types of cancer and the SNPs identified and studied.
3. CYP19A1 polymorphisms in different cancers
3.1. Variations in CYP19A1 gene and breast cancer
Breast cancer remains as the most frequently occurring cancer in all races and all ethnic 
groups (https://nccd.cdc.gov/uscs/toptencancers.aspx). Estrogens affect proliferation and 
growth of the cells in the breast. Thus, polymorphisms of the genes, which are involved in 
the estrogen biosynthesis and metabolism, have been regarded as factors affecting the risk of 
breast cancer. Research conducted since the early 1970s confirmed that the major risk and pre-
disposing factor for breast cancer is increased exposure to estrogens and progesterone [49]. 
Obesity was also shown to be one of the factors since adipose tissues are an important source 
of endogenous estrogens [50]. Furthermore, local production of estrogens in the breast tissue 
was shown to play a major role in elevating hormone levels in the breast tissue, which in turn 
accelerates proliferation and growth of breast cells and subsequent progression to malignant 
transformation [51]. Genetic factors increase susceptibility to develop breast cancer, and in 
the 1990s, the identification of two breast cancer susceptibility genes, BRCA1 and BRCA2 [52], 
turned the attention of breast cancer research to the identification of possible genetic mark-
ers of breast cancer susceptibility. Extensive research has led to accumulation of knowledge 
about genetic variation in different genes, including the CYP19A1 gene, due to its gene prod-
uct, aromatase. Table 2 summarizes some of the reports on SNPs in CYP19A1 and shows that 
there are contradictions in different reports about the contribution of a SNP to breast cancer 
risk and there are population differences in the influence of the SNP on clinical presentation.
The rs10046 polymorphism is a C/T transition in the 3′ UTR of CYP19A1 gene. It has been 
classified as a benign variant, which has recently been linked to aromatase deficiency (https://
www.ncbi.nlm.nih.gov/clinvar/RCV000323501/). Recently, Farzaneh et al. [54] showed that 
there was a significant differences in allele and genotype frequencies for rs10046 in Iranian 
population with and without breast cancer (p-value = 0.01, OR (CI 95%) = 1.59 (1.1–2.3), 
p-value = 0.04, OR (CI 95%) = 1.7 (1.1–2.5), respectively). Zhang et al. [79] reported that among 
the ER+ Chinese women, the T allele of rs10046 was significantly associated with premeno-
pausal breast cancer risk. Yoshimoto et al. [69] studied rs10046 polymorphism in Japanese 
women and reported that the C allele could be regarded as a risk predictor of breast cancer 
(p = 0.007). However, other studies on different populations failed to show any association. 
A study on Greenlandic Inuit women did not show any effect of rs10046 on the risk of breast 
cancer (%) [53]. Pineda et al. [72] showed that in a Spanish population the C allele may be 
linked to an increased risk of breast cancer. However, when they extended their findings to 
a meta-analysis, the association was lost. They concluded that it is possible that the effect of 
rs10046 is modified in the presence of other variants. Zins et al. [71], recently, showed that 
though rs10046 does not link to breast cancer risk, but the TT genotype affects the age of onset, 
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CYP19A1 SNP Population/study location Clinical implication Reference
rs10046 Inuit women Nonsignificant association with BC [53]
rs10046 Iranian Significant association with BC [54]
rs762551
rs4646
Swedish Predictive marker for early breast 
cancer events in AI-treated patients with 
ER-positive tumors
[8]
rs6493497 USA Associated with decreased bone density 
with AI treatment
[10]
rs4646 China AA is significantly associated with 
improved clinical outcome of hormone 
therapy; prolonged DFS
[55]
rs4646, rs10046, rs700518, 
rs749292 rs2289106, 
rs3759811, rs4775936
American Significantly associated with decreases in 
triglycerides on letrozole treated
[12]
rs10046 Xinjiang Uigur women TC genotype and an abortion can reduce 
the risk of the breast cancer
[56]
rs934635, rs60271534, 
rs700518
A meta-analysis Treatment response [57]
rs700518 Italy Treatment response [58]
rs4646, rs10046, rs936308 American Were associated with bone AEs [65]
rs4646 Chinese Related to DFS in early breast cancer 
and that the prognosis index of the 
homozygous for the minor allele (AA) 
may depend on menopause status
[66]
rs700518,
rs11856927
American ancestry, 
Hispanic Americans, and 
Mexico Whites
Significantly associated with increased 
breast cancer risk
[67]
rs4775936 UK AI metabolism [68]
rs10046 Japanese Significant risk predictor [69]
rs700519 India Could be used as molecular markers to 
assess breast cancer
[70]
rs10046 Austrian population Association with clinical characteristics [71]
rs10046 Spain Related to levels of circulating estradiol 
and to the estradiol/testosterone ratio
[72]
rs4646, rs1065779,
rs1870050
Taiwan Associated with poor survival of 
premenopausal women but does not 
affect survival of postmenopausal women
[73]
rs4646 American May serve as a prognostic marker of the 
response to anastrozole in patients with 
MBC
[74]
rs10046, rs4646, rs2830, 
rs9926298, and rs9939609
China Nonsignificant association with BC [75]
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where individuals carrying TT may develop breast cancer at an age younger than 50 years. 
It was also shown that the genotypes of rs10046 may influence the levels of estrogens and 
estrogen/testosterone ratio and also play a role in modulating the levels of other biochemical 
parameters [72].
The rs4646 polymorphism is an A/C transversion, located in the 3′ UTR of the CYP19A1 gene. 
Some studies show it to be significantly associated with an increased risk of breast cancer. 
Among the Swedish breast cancer patients, rs4646 was strongly associated with the risk of 
breast cancer and the histological grade of the disease [78]. The A allele was associated with 
low histological grade and small tumor size (p = 0.001 and 0.015). Shao et al. [66] showed that 
AA is related to longer disease-free survival in Chinese breast cancer patient’s population com-
pared to the CC and CA genotype of the rs4646 genotype. Fasching et al. [80] showed that the 
rs4646 may influence disease-free intervals in breast cancer patients. They concluded that this 
variant may influence the prognosis of the disease but not through affecting estrogen levels.
Santa-Maria et al. [84] have recently reported that several SNPs influence the plasma lipid 
levels in patients treated with letrozole, where rs4646, rs10046, rs700518, rs749292, rs2289106, 
rs3759811, and rs4775936 decreased triglyceride levels and had a variable effect on the level 
of HDL-C.
A number of other SNPs have been investigated in breast cancer; some are associated with the 
risk of breast cancer, while others are not (Table 2). Some influence the clinical presentation of 
the disease, the prognosis, and the disease-free intervals, while still others modulate the effect 
of treatment and the associated complications.
CYP19A1 SNP Population/study location Clinical implication Reference
rs700518, rs10459592, and 
rs4775936
Korea Significantly associated with clinical 
efficacy
[76]
rs10046, rs4646, rs74929,
rs727479
Italian The aromatase enzyme function is not 
affected by polymorphisms of CYP19A1 
gene in postmenopausal BC patients
[77]
rs4646,
rs7167936
Swedish Involved in both breast cancer risk and 
prognosis
[78]
Arg264Cys Chinese No association [59]
Arg264Cys Korean Increased breast cancer risk [60]
Arg264Cys Chinese No association [61]
rs1008805 USA G allele associates with breast cancer [62]
rs2236722 Japanese Trp more frequent in ER+ [63]
rs1870049, rs1004982, 
rs28566535, rs936306, 
rs11636639, rs767199, 
rs4775936, rs11575899, 
rs10046, rs4646
Chinese No association [64]
Table 2. Some of the SNP association studies reported in breast cancer.
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3.2. Variations in CYP19A1 gene and endometrial cancer
Endometrial cancer (EC) is one of the most frequently encountered gynecologic malignancies, 
and a strong association is shown to exist between excess of estrogens and initiation and pro-
motion of endometrial cancer [81]. As early as 1975, it became evident that estrogen may act as 
a carcinogen when unopposed by an adequate amount of progesterone. Many studies dem-
onstrated higher risk of endometrial cancer in females on hormone replacement therapy [82]. 
Since exposure to endogenous estrogens was regarded as an important determinant of risk 
of endometrial cancer, several studies were initiated to identify genetic variants and the role 
they play as risk factor for the development of endometrial cancer. One of the earliest stud-
ies was reported from Russia and implicated genetic variants of CYP19A1 in the etiology of 
endometrial cancer [38]. Mikhailova et al. [83] investigated the C --> T transition (Arg264Cys) 
in exon 7 of CYP19A1 gene but did not find any association. G/A and T/C polymorphisms of 
CYP19A1 were investigated, but no significant association was identified (p > 0.05) [85]. Tao et 
al. [86] investigated several SNPs (rs1065779, rs700519, rs28566535, rs752760, and rs1870050) 
in CYP19A1 gene. The results showed that the rs1870050 in the promoter region associates 
inversely, where the genotypes CC and AC had a 0.81 (95% CI = 0.68–0.97) and 0.58 (95% 
CI = 0.42–0.80), respectively. Gulyaeva et al. [87] showed that the CT genotype of R264C poly-
morphism increases the risk of endometrial cancer significantly with an OR = 3.73, p = 0.0004. 
Setiawan et al. [88] showed the association of the A allele of rs749292 and rs727479 with 
increased risk of endometrial cancer and a 10–20% increase in circulating estrogen levels in 
postmenopausal women. In another study, the A allele of rs4775936 was significantly associ-
ated (OR (per allele) = 1.22; 95% CI = 1.01–1.47; p(trend) = 0.04), while the T allele of rs10046 
was marginally associated with increased risk of endometrial cancer (OR (per allele) = 1.20; 
95% CI = 0.99–1.45; p(trend) = 0.06) [89]. Recently, Thompson et al. [18] reported the results 
of a genome-wide study and showed that rs727479 was associated most significantly with 
endometrial cancer and elevation in circulating estrogen (E2). Further studies are required in 
different populations to confirm the association of genetic variants of CYP19A1 with endo-
metrial cancer.
3.3. Variations in CYP19A1 gene and prostate cancer
Prostate cancer is among the most frequently encountered non-cutaneous malignancy in men. 
Extensive research has been carried out to identify the etiology and pathological mechanisms, 
but the mechanism of prostate cancer development is not fully clear. Several factors have been 
implicated in its etiology including environmental, dietary, hormonal, lifestyle, and genetic 
factors. Studies have confirmed that estrogens may be closely involved in predisposing to or 
even causing cancer [90]. Aromatase is shown to be altered in patients with prostate cancer, 
and its expression is elevated almost 30 times in the cancer tissue compared to the normal 
tissue [91, 92]. The mechanisms by which estrogens induce carcinogenesis in prostate tissue 
have been hypothesized in several studies and involve genotoxicity, after chronic inflamma-
tion, epigenotoxicity, hyperprolactinemia, and prostatic ER-mediated changes. The genetic 
factors in the patient are gaining considerable interest, and genetic polymorphisms are being 
regarded as prognostic predictors of metastatic prostate cancer [93].
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A few studies have reported the influence of rs700519 on prostate cancer risk. This SNP is a 
C > T transition in exon 7 of CYP19A1 gene and results in the substitution of Arg at position 
264 by Cys. No association was reported among Bulgarians [94], African Americans [95], and 
Japanese [96]. However, a study on North Indian population showed that the variant Cys 
was associated with statistically significant increased risk of prostate cancer (OR = 2.28; 95% 
CI = 1.20–4.35; p = 0.012) [97]. Another report on Japanese showed that when prostate cancer 
patients were stratified according to clinical stage and pathologic grade of cancer, the CT and 
TT genotypes were associated significantly with high-grade carcinoma (OR = 2.59; 95% CI = 
1.47–4.46; p = 0.048) [98]. A study on Caucasians showed that the C/T mutation was associated 
with prostate cancer risk, with only borderline significance after age and BMI adjustment. 
Interestingly, when the effect of the C/T mutation was evaluated with a mutation in androgen 
receptor (AR), the significance of the association with prostate cancer risk increased consider-
ably [99]. Mononen et al. [100] explored the association between 18 variants and prostate can-
cer risk and identified a novel SNP, T201M. This SNP showed association with prostate cancer 
(odds ratio (OR) = 2.04; 95% confidence interval (95% CI) = 1.03–4.03; p = 0.04). Onsory et al. 
[97] showed that Cys allele in exon 7 of CYP19A1 was also associated with statistically signifi-
cant increased risk of prostate cancer (OR = 2.28; 95% CI = 1.20–4.35; p = 0.012). Other studies 
also showed that CYP19A1 polymorphisms may influence prostate cancer risk and survival 
by modifying promoter activity, with subsequent effects on the sex hormone milieu [101].
A study recently reported on two populations of African ancestry failed to show any associa-
tion between rs60271534 and prostate cancer risk [17]. Another SNP 1531 C > T was investi-
gated in the Turkish prostate cancer patients, but no significant association was observed [102]. 
Lévesque et al. [103] reported a study in which results obtained in Caucasians and Taiwanese 
were compared. It was shown that rs12900487, rs4441215, and rs2470152 in CYP19A1 gene 
do not follow Hardy-Weinberg equilibrium and did not differ in their frequency between the 
patient and control group. Two other SNPs rs1870050 and rs2446404 significantly increased 
the risk of prostate cancer in the Caucasian population, while in the Taiwanese, only rs1870050 
was associated significantly in the Caucasians but not in the Taiwanese [103].
The effect of two or more coexisting SNPs in influencing predisposition to prostate cancer is 
shown in several studies, thereby implying that the SNPs may behave synergistically or have 
antagonistic effect and thus bringing further heterogeneity to SNP action [96]. Cussenot et 
al. [32] reported that the long allele (>175 bp) of the TTTA repeat of CYP19A1, when existing 
with V432L polymorphism of CYP1B1, increases the risk of prostate cancer significantly. This 
effect was more obvious in the younger patients. Huang et al. [42] working on a Taiwanese 
population reported that the risk of developing prostate cancer increased significantly (from 
OR = 1.59; 95% CI = 1.04–2.44; p = 0.044), when TCT del/del genotype of CYP19A1 coexists 
with (TTTA)7. The coexisting ins allele and (TTTA)12 also in the CYP19A1 reduced the risk 
of developing prostate cancer. More recently, Kachakova et al. [94] have shown that the 7/8 
genotype of (TTTA)n repeat polymorphism in CYP19A1, when coexisting with the C allele of 
rs1056837 in CYP1B1, predisposes to prostate cancer, while the 8/9 and the 7/12 genotypes 
of (TTTA)n of CYP19A1 when existing with the C allele of CYP1B1 associate with lower risk 
of prostate cancer and a reduced risk for aggressive disease.
Interestingly, it was shown that some of the SNPs in CYP19A1 gene have a significant effect 
on the level of circulating steroid hormones including LH, testosterone, estradiol, SHBG, and 
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indices of insulin sensitivity. However, no association was reported between these polymor-
phisms and non-hormonal parameters including anthropometric parameters, blood pressure, 
lipids, hemoglobin, and prostate-specific antigen [104].
The plasma level of estrogens may also be altered by the presence of different SNPs in the 
CYP19A1 gene. rs2470152, an intronic SNP, is significantly associated with the serum level of 
E2, while in individuals, the presence of rs2470152 results in the elevation of both E1 and E2 
in men [105].
The presence of some SNPs also influences the effect of different nutritional and therapeutic 
agents used for protection from cancer. Sonoda et al. [106] report from Japan that the protec-
tive effect shown by isoflavones against prostate cancer is modified by the (TTTA) long repeat 
alleles and coexisting minor alleles of rs10046 in CYP19A1, even if the isoflavones are used at 
concentrations as high as 60 mg/day. On the other hand, homozygosity for the major allele 
of rs10046 in CYP19A1 and also with coexisting short repeats of (TTTA) reduces the risk of 
prostate cancer development.
3.4. Variations in CYP19A1 gene and colorectal cancer
It is well documented that estrogens play a role in the development and progression of 
colorectal cancer (CRC) [107–109]. The beneficial role played by estrogens in preventing CRC 
is obvious since males have a higher prevalence of CRC than premenopausal females, but the 
prevalence increases in menopausal females. Furthermore, females on hormone replacement 
therapy have a lower susceptibility to CRC [110]. However, it is shown that estrogens are 
locally produced in the colorectal tissue and result in a higher level of E2 and a lower level of 
E1. This imbalance in E2/E1 ratio may result in an increase in cell proliferation and concomi-
tant decrease in apoptosis, thus increasing the risk of CRC [111–113]. Normally, in the colon, 
E2 is converted to E1 by 17β-HSD2 and 17β-HSD4. The E1 is antiproliferative, and the E2/E1 
ratio keeps a check on the cell cycle. In colon cancer since this ratio is altered, proliferation 
is accelerated [111, 112]. A study on Chinese men showed that there were elevated E2 levels 
and the presence of CT/TT genotype of ESR2 receptor increased the risk of CRC to 2.3 (95% 
CI = 1.4–3.9), compared to those who had lower levels of E2 and the ESR2 genotype CC [114].
Polymorphisms are reported in CYP19A1 gene, and some result in increased risk of CRC. 
Lin et al. [115] studied Caucasian patients of the European origin and genotyped the patients 
and controls for 13 different SNPs (rs4646, rs10046, rs2414096, rs727479, rs1008805, rs749292, 
rs93606, rs3751591, rs1004984, rs2445762, rs2446405, rs2740144, and rs32445765), distributed 
all over the CYP19A1 gene. Only one SNP rs10046 showed a significant association with CRC 
risk. However, the significance was lost after correction for multiple comparisons. In a study 
from the USA, Slattery et al. [110] reported significant association of four SNPs (rs12591359, 
rs17523880, rs1961177, rs3751591) with increased risk of colon cancer and another four which 
increased the risk of rectal cancer [116]. However, after adjustment for multiple comparisons, 
only one SNP (rs12591359) showed significant association (OR = 1.44; 95% CI = 1.16–1.80). 
The AA genotype of this SNP was associated with an increased risk of cancer of the colon 
and decreased risk of the cancer of rectum. We genotyped Saudi CRC patients for six SNPs 
(rs4774585, rs936308, rs4775936, rs700518, rs28757184, and rs4646) in the CYP19A1 gene but 
failed to see any association with CRC risk [117]. Lin et al. [116] studied haplotypes in the 
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CYP19A1 gene and identified one haplotype block, which associated with CRC, most likely 
reflecting association with the tagging SNP, rs1902584, in the block.
It has also been reported that aromatase also participates in metabolizing various compounds 
produced endogenously, including sex hormones, lipids, and other lipid derivatives. The 
rate of metabolism of these compounds depends on the amount and activity of the enzyme, 
which in turn may be altered by the alleles of the different SNPs. Metabolic end products pro-
duced may increase or decrease the risk of CRC and hence the interindividual differences in 
inherited metabolic susceptibility to CRC. Inflammatory response to different exogenous and 
endogenous factors may also have a role in CRC [110].
3.5. Variations in CYP19A1 gene and ovarian cancer
Several clinical trials have provided evidence implicating hormone replacement therapy as a 
risk factor for development of ovarian cancer. However, the role played by estrogen in the eti-
ology of ovarian cancer has yet to be unveiled. Polymorphisms in CYP19A1 gene have been 
investigated in a few studies, to identify possible risk markers. Goodman et al. [118] conducted 
multiethnic (Japanese, Caucasian, Hawaiian, Filipino, and others) case-control study in Hawaii 
and investigated two SNPs (rs749292 and rs727479) in relation to ovarian cancer. They showed 
that the A allele of rs749292 was associated positively with ovarian cancer risk in a codominant 
model for all races combined, while the rs749479 did not show any association [118]. Both alleles 
increased the plasma estrogen levels by 10–20%. In an Australian population, no association was 
seen between rs10046 and ovarian cancer [119]. In a Polish population, several polymorphic 
loci were investigated, but no association was observed with any of the studied SNPs. More 
investigations are required to confirm association if any between the SNPs and ovarian cancer.
3.6. Variations in CYP19A1 gene and hepatocellular carcinoma
Worldwide, the prevalence of hepatocellular carcinoma (HCC) is high, classifying it as one of 
the most common malignancies. Studies have suggested that sex hormones, including andro-
gen and estrogen, may be involved in HCC development and progression [120], pointing 
toward aromatase variants in HCC development. However, studies on CYP19A1 polymor-
phism and the risk of HCC are few. Yuan et al. [121] failed to show any association between a 
non-synonymous SNP at codon 39 of the CYP19A1 gene, which causes substitution of Trp by 
Arg and results in the synthesis of a nonfunctional aromatase. A positive association between 
A/C transversion and HCC risk was reported by Koh et al. [122]. This polymorphism occurs 
in the exon I.6 promoter of the CYP19A1 gene and is located in a consensus sequence for a 
TFIID binding site. The C allele increases the expression of CYP19A1 significantly, thereby 
increasing the synthesis of estrogens and androgens. Further studies are required to identify 
other risk markers for HCC in the CYP19A1 gene.
3.7. Variations in CYP19A1 gene and esophageal adenocarcinoma
Esophageal adenocarcinoma (EA) prevalence is on the rise in the young Western popula-
tion. A strong gender bias is shown in epidemiological studies, with a sex ratio of 8:9.1. It 
is suggested that the estrogens may be a protecting factor in females, since estrogens have 
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been shown to stimulate apoptosis and decrease the growth of the esophageal squamous cells 
[123]. It also decreases the expression of Ki-67 while increasing E-cadherin expression [124]. 
However, not many studies have explored the role of SNPs in CYP19A1 gene and the risk of 
EA development. Wu et al.  [125] studied the role of rs2445762 of CYP19A1 and showed that 
there was a significant association between this SNP and an early onset of EA (≤55 vs. >55 
years), all p < 0.05 after adjusting for covariates and false discovery rate.
Recently, a study by Lagergren et al. [126] pooled 14 studies from three continents (Australia, 
Europe, and North America) and investigated the effect of 60 SNPs in CYP19A1 gene as a risk 
factor for EA. However, no significant association was identified for any of the SNPs in any 
of the populations. Further studies are required in different populations to identify possible 
association between CYP19A1 polymorphisms and EA risk.
3.8. Variations in CYP19A1 gene and gastric cancer
Gastric cancer is the fourth most common cause of cancer-related death in the world [http://
www.who.int/mediacentre/factsheets/fs297/en/]. Studies have suggested that long exposure 
to estrogens, of ovarian or exogenous origin, may provide a protection against development 
of cancer [127, 128]. This finding has led to the implication of estrogen receptor defects in the 
development of gastric cancer [129]. There are very few reports on the association between 
CYP19A1 gene polymorphism and gastric cancer risk. Freedman et al. [130] investigated 58 
SNPs in six genes (COMT, CYP1B1, CYP17A1, CYP19A1, HSD17B1, and SHBG) which are 
involved in the biosynthesis of estrogen and androgen. None of the CYP19A1 gene showed 
any association with gastric cancer risk. More recently, Cho et al. [131] conducted a popula-
tion-based genetic association study, in which they investigated the role of genes for proteins 
involved in the steroid hormone biosynthesis pathways. Of the 108 SNPs investigated in five 
genes (CYP19A1, HSD3B1, HSD17B2, CYP17A1, HSD17B1), 10 SNPs in CYP19A1 were sig-
nificantly associated with the risk of gastric cancer. They concluded that CYP19A1 may be an 
important player in elevating the risk of gastric cancer and could be considered as a genetic 
marker for gastric cancer susceptibility (p < 0.05). Since the association is unclear, further 
studies on CYP19A1 gene polymorphism and the risk of gastric cancer, in different popula-
tions, are warranted and may help in the identification of possible genetic marker.
3.9. Variations in CYP19A1 gene and testicular germ cell tumor
In young men, testicular germ cell tumor (TGCT) is reported to be the most common cancer. 
It is hypothesized that an imbalance in the in utero level of androgens and estrogens may be 
the major predisposing factor in influencing TGCT risk. Kristiansen et al. [132] conducted an 
investigation on Norwegian-Swedish case-parent trios and genotyped 105 SNPs in 20 genes 
whose gene products were involved in the sex hormone pathways. Three SNPs (rs2414099, 
rs8025374, and rs3751592) showed a statistically significant association with TGCT risk in 
the case-parent analysis. For each of the studied SNP, the T alleles were associated with an 
elevated risk of TGCT (OR = 1.30, 1.30, and 1.21, respectively). No differences were identi-
fied in allelic effect estimates when the parental inherited genetic variation was correlated 
with the TGCT risk in the offspring. Furthermore, no differences were observed between the 
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Norwegian and the Swedish populations for each of the studied SNP. It was concluded that 
aromatase may be a factor playing a role in the etiology of TGCT. However, this statement 
needs confirmation from further population-based studies.
4. Effect of SNPs on prognosis and survival of breast cancer patients
Some of the SNPs in CYP19A1 gene have been linked to disease prognosis and survival. It 
was shown that rs28566535, rs730154, and rs936306 are significantly associated with plasma 
levels of estrone as well as with breast cancer survival [133, 134]. Long et al. [135] showed an 
association between genetic polymorphisms of the CYP19A1 gene and breast cancer survival. 
Udler et al. [136] presented preliminary evidence suggesting that germline variation in genes 
involved in steroid hormone metabolism may alter breast cancer prognosis.
5. Effect of SNPs on hormonal parameters
Variations related to the effect of SNPs on biochemical and hormonal parameters are also 
reported in a few studies. Huhtaniemi et al. [104] did not find any associations between 
CYP19A1 polymorphism and non-hormonal variables including anthropometric parameters, 
blood pressure, cognition sexual hemoglobin, blood lipids, and hemoglobin. Kidokoro et al. 
[137] showed that SNPs in CYP19A gene alter the levels of estrogens. Eriksson et al. [105] 
presented data showing that rs2470152 is clearly associated with serum E2 and E1 levels in 
men. Other investigations show the association between SNPs rs10046 and rs11575899 and 
endogenous estrogen levels [138, 139].
Estrogen levels are influenced by the presence of different genotypes of a SNP, as reported in 
some studies but not in others. Thompson et al. [18] showed in a comprehensive study that the 
SNP rs727479 was associated most strongly with circulating E2 concentrations in postmeno-
pausal healthy controls and its effect was stronger in obese females. Cai et al. [140] showed 
that rs1902584 in block 1 was associated with estradiol only in overweight postmenopausal 
women.
6. Influence of SNPs in CYP19A1 gene on treatment with aromatase 
inhibitors
The treatment strategies have been extensively investigated in breast cancer, due to the high 
prevalence and associated morbidity and motility. There are a number of options for the treat-
ment of the different types of cancer, and generally a multidisciplinary approach is preferred. 
The options are dependent on the type of cancer, patients’ history, and the characteristics of the 
tumor. Some of the more common treatment strategies are surgery, radiotherapy, chemotherapy, 
and hormonal therapy. The two common antiestrogen therapies are tamoxifen and aromatase 
inhibitors. The former is used generally for the treatment of ER+ breast cancer in premenopausal 
women, while the latter is under investigation for treatment of premenopausal breast cancer 
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patients. In the postmenopausal women, the aromatase inhibitors (AIs) are reported to have a 
higher efficacy compared to tamoxifen in the postmenopausal group in relation to metastasis 
and prognosis in the presence of adjuvant treatment. However, ethnic differences and interindi-
vidual differences are frequently reported and are related to genetic variations.
As stated in the earlier part of this chapter, there are a significantly large number of SNPs in 
the CYP19A gene. Some of these have an influence on aromatase activity and hence influence 
the level of estrogens. Such mutations play a role in the effectiveness of the clinical efficacy 
related to treatment strategies.
Several studies have evaluated the effect of the genotype on the efficacy of the AI used for 
treatment of cancer. There are several contradictory reports, and the SNP may or may not 
associate with AI treatment complications. Those SNPs, which influence aromatase activity 
and are associated with elevated levels of estrogens, such as rs6493497 and rs7176005, seem to 
alter the effectiveness of AI [141]. On the other hand, it was shown that rs700518, rs10459592, 
and rs4775936 were significantly associated with higher clinical benefit rate with letrozole 
treatment [142]. Ferraldeschi et al. [68] investigated the effect of 56 SNPs on AI treatment and 
concluded that none of the variants independently were associated with improved AI efficacy 
and emphasized the significance of further studies on genetic biomarkers as prognostic fac-
tors in pharmacogenetic studies.
Table 3 lists a few SNPs and their influence on the outcome of AI treatment.
SNP Effect on AI treatment Reference
rs6493497 Almost 13-fold increase estradiol concentration in post-anastrozole. Alters effectiveness of 
AI treatment associated with decreased bone density in the exemestane-treated patients
[141]
rs7176005 Almost 11-fold increase estradiol concentration in post-anastrozole. Alters effectiveness 
of AI treatment
[141]
rs4646 Associated with poor response to the AI, letrozole (p = 0.03) [134, 142]
rs700518 —GG genotype of rs700518 increases risk for significant loss of fat-free mass and increase 
in truncal fat with AI therapy
—AA genotype of rs700518 is at risk for AI-associated bone loss
[142, 143]
rs700518 Significantly associated with higher clinical benefit rate with letrozole treatment [142]
rs10459592
rs4775936
rs1062033 CC genotype in postmenopausal patients had lower spine and hip bone mineral density 
compared with the GG genotype. No correlation with AIs was established
[144]
rs60271534 Lower incidence of AI-associated arthralgia. But the effect was not definite as two 
different AIs were used
[145]
rs10046 Five-year disease-free survival was enhanced in premenopausal women on AI therapy [146]
rs700519 Associated with lower aromatase activity, but no studies showed a significant correlation 
with AIs
[80]
AI, aromatase inhibitor.
Table 3. SNPs in CYP19A1 gene and their interaction with AI treatment.
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7. Conclusions
Aromatase is an essential enzyme required for the synthesis of estrogens. The polymorphic 
forms of aromatase gene seem to contribute to the development of different forms of cancer, and 
several avenues await exploration. Population differences in the frequencies of different SNPs 
and the association with the different disease states need further detailed study. Association 
studies are required to confirm if there is a risk or protective effect of the SNP genotype. Studies 
on disease prognosis, in relation to the different genotypes of a SNP, are required. Finally, the 
influences of the SNP on treatment strategies are warranted. Individualized medicine is the 
dream of present-day clinicians. The role played by SNPs may contribute to achieve this dream.
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